KNSA Kiniksa Pharmaceuticals International, plc
Stock · NasdaqGS · United Kingdom · Healthcare · GB00BRXB0C07
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Kiniksa Pharmaceuticals International, plc, and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
93.86 USD
+6.25%
52-week range
37.02 – 98.48
Dividend yield—
Market cap7.4B
NowoTrade score
56 Grade A
Price history
Daily prices in USD.
Updated 08 Nov 2026 14:27. Information, not advice.
Results
Next results
23 Feb 2027
in 107 days · 08:00 · estimate 0.28
Last results
0.56 vs 0.31 estimated
27 Oct 2026 · Beat +79.2%
Beat the estimate
4 of 12
8 missed · 0 in line · 3 beats in a row
Average surprise
-108.0%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 23 Feb 2027 08:00 | 0.28 | — | — | Upcoming |
| 27 Oct 2026 07:00 | 0.31 | 0.56 | +79.2% | Beat |
| 28 Jul 2026 07:00 | 0.28 | 0.30 | +5.3% | Beat |
| 28 Apr 2026 07:00 | 0.16 | 0.27 | +68.8% | Beat |
| 24 Feb 2026 07:00 | 0.40 | 0.17 | -57.3% | Miss |
| 28 Oct 2025 07:00 | 0.37 | 0.23 | -37.3% | Miss |
| 29 Jul 2025 07:00 | 0.26 | 0.23 | -11.3% | Miss |
| 29 Apr 2025 07:00 | 0.28 | 0.11 | -61.2% | Miss |
| 25 Feb 2025 07:00 | 0.13 | -0.12 | -192.3% | Miss |
| 29 Oct 2024 07:00 | 0.07 | -0.18 | -366.7% | Miss |
| 23 Jul 2024 07:00 | 0.01 | -0.06 | -999.6% | Miss |
| 23 Apr 2024 07:00 | -0.08 | -0.25 | -212.5% | Miss |
| 28 Feb 2024 07:00 | -0.09 | 0.35 | +488.9% | Beat |
| 31 Oct 2023 07:00 | -0.16 | -0.20 | -25.0% | Miss |
| 25 Jul 2023 07:00 | -0.13 | 0.21 | +261.5% | Beat |
| 02 May 2023 07:00 | -0.16 | -0.18 | -9.1% | Miss |
| 28 Feb 2023 08:00 | -0.14 | 0.06 | +142.9% | Beat |
| 01 Nov 2022 08:00 | 0.83 | 3.18 | +283.1% | Beat |
| 03 Aug 2022 07:00 | -0.39 | -0.29 | +26.3% | Beat |
| 03 May 2022 08:00 | -0.26 | -0.36 | -40.3% | Miss |
| 22 Feb 2022 08:00 | -0.40 | -0.51 | -27.9% | Miss |
| 01 Nov 2021 08:00 | -0.63 | -0.44 | +29.9% | Beat |
| 03 Aug 2021 08:00 | -0.77 | -0.61 | +21.3% | Beat |
| 04 May 2021 08:00 | -0.63 | -0.72 | -14.9% | Miss |
| 23 Feb 2021 08:00 | -0.61 | -0.79 | -30.0% | Miss |
| 05 Nov 2020 07:00 | -0.59 | -0.66 | -11.4% | Miss |
| 30 Jul 2020 07:00 | -0.58 | -0.65 | -11.1% | Miss |
| 28 Apr 2020 08:00 | -0.62 | -0.48 | +22.1% | Beat |
| 26 Feb 2020 07:00 | -0.76 | -0.58 | +23.7% | Beat |
| 28 Oct 2019 16:00 | -0.70 | -0.49 | +29.9% | Beat |
| 12 Aug 2019 16:00 | -0.76 | -0.68 | +10.2% | Beat |
| 02 May 2019 07:00 | -0.79 | -0.73 | +7.8% | Beat |
| 07 Mar 2019 07:00 | -0.74 | -0.88 | -18.6% | Miss |
| 01 Nov 2018 08:00 | -0.53 | -0.51 | +4.7% | Beat |
| 06 Aug 2018 07:00 | -0.50 | -0.47 | +6.9% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 677.6M | +60.1% | 59M | 8.7% | 0.75 | +225.0% | 136.4M |
| 2024 | 423.2M | +56.6% | -43.2M | -10.2% | -0.60 | -400.0% | 25.4M |
| 2023 | 270.3M | +22.7% | 14.1M | 5.2% | 0.20 | -92.3% | 13.2M |
| 2022 | 220.2M | — | 183.4M | 83.3% | 2.60 | — | 5.7M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 28 Feb 2025 | 19.67 | 20.49 | 19.58 | 20.28 | +3.31% | 733,800 | |
| 27 Feb 2025 | 19.64 | 20.04 | 19.45 | 19.63 | -0.30% | 446,900 | |
| 26 Feb 2025 | 19.97 | 20.16 | 19.67 | 19.69 | -0.15% | 1,247,500 | |
| 25 Feb 2025 | 19.20 | 20.15 | 19.20 | 19.72 | +0.46% | 713,700 | |
| 24 Feb 2025 | 20.02 | 20.04 | 19.63 | 19.63 | -1.95% | 383,900 | |
| 21 Feb 2025 | 19.90 | 20.09 | 19.50 | 20.02 | +1.68% | 404,100 | |
| 20 Feb 2025 | 19.63 | 19.81 | 19.31 | 19.69 | -0.15% | 215,300 | |
| 19 Feb 2025 | 19.57 | 20.20 | 19.54 | 19.72 | +0.87% | 460,600 | |
| 18 Feb 2025 | 19.70 | 20.01 | 19.43 | 19.55 | -0.96% | 244,200 | |
| 14 Feb 2025 | 19.92 | 20.32 | 19.58 | 19.74 | +0.46% | 640,900 | |
| 13 Feb 2025 | 19.28 | 19.68 | 19.17 | 19.65 | +1.92% | 268,800 | |
| 12 Feb 2025 | 19.21 | 19.91 | 19.17 | 19.28 | -2.13% | 244,000 | |
| 11 Feb 2025 | 19.20 | 19.75 | 18.12 | 19.70 | +0.51% | 569,500 | |
| 10 Feb 2025 | 19.62 | 19.96 | 19.37 | 19.60 | +0.56% | 357,200 | |
| 07 Feb 2025 | 20.30 | 20.36 | 19.39 | 19.49 | -3.94% | 379,500 | |
| 06 Feb 2025 | 19.75 | 20.73 | 19.60 | 20.29 | +3.36% | 1,684,700 | |
| 05 Feb 2025 | 18.80 | 19.84 | 18.52 | 19.63 | +4.75% | 830,800 | |
| 04 Feb 2025 | 18.96 | 19.19 | 18.73 | 18.74 | -0.74% | 550,000 | |
| 03 Feb 2025 | 19.58 | 19.60 | 18.85 | 18.88 | -3.67% | 555,400 | |
| 31 Jan 2025 | 20.10 | 20.10 | 19.55 | 19.60 | -1.41% | 570,300 | |
| 30 Jan 2025 | 20.83 | 20.83 | 19.76 | 19.88 | -3.78% | 547,200 | |
| 29 Jan 2025 | 20.24 | 20.89 | 20.24 | 20.66 | +2.38% | 535,600 | |
| 28 Jan 2025 | 20.80 | 20.90 | 20.18 | 20.18 | -2.79% | 578,300 | |
| 27 Jan 2025 | 20.07 | 20.78 | 19.57 | 20.76 | +3.64% | 918,800 | |
| 24 Jan 2025 | 19.76 | 20.58 | 19.52 | 20.03 | +1.32% | 797,400 |
Page 18 of 51
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Kiniksa Pharmaceuticals (NASDAQ:KNSA) Clears the Minervini Trend Template but Awaits a Lower-Risk Entry (opens in a new tab) ChartMill · 03 Nov 2026 13:11
- Kiniksa (KNSA) Stock Jumps As Q3 Results Fuel Growth Debate (opens in a new tab) Simply Wall St. · 28 Oct 2026 07:11
- Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors (opens in a new tab) Motley Fool · 27 Oct 2026 18:11
- Kiniksa Pharmaceuticals, Ltd. Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 27 Oct 2026 17:53
- Kiniksa (KNSA) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 27 Oct 2026 16:43
- What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings Call (opens in a new tab) MarketBeat · 27 Oct 2026 16:04
- Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass Estimates (opens in a new tab) Zacks · 27 Oct 2026 11:50
- Biotech Stocks To Watch: Regeneron Partner Has Breakout In Sight (opens in a new tab) Investor's Business Daily · 14 Oct 2026 21:08
- Kiniksa Pharmaceuticals International (KNSA) On The ARCALYST Story And Whether Shares Look Fully Valued (opens in a new tab) Simply Wall St. · 24 Sep 2026 00:14
- Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why (opens in a new tab) Zacks · 17 Sep 2026 17:13
- Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat (opens in a new tab) Investor's Business Daily · 10 Sep 2026 17:35
- Kiniksa's Sales Are Expected To Decline — Why That's All According To Plan (opens in a new tab) Investor's Business Daily · 21 Aug 2026 21:11
- Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3 (opens in a new tab) MarketBeat · 15 Aug 2026 02:01
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 88.34 USD
- Market cap
- 7.4B
- Exchange
- NasdaqGS
- Country
- United Kingdom
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 12.5 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 13.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 18.1 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 2.3 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 8.9 / 10 |
|
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A).
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 71.11× | Weak | 30.3× |
| P/E (forward) | 43.01× | Weak | 14.94× |
| Price / book | 10.37× | Weak | 3.81× |
| Price / sales | 7.8× | Weak | 3.19× |
| EV / EBITDA | 51.48× | Weak | 12.63× |
| Free cash flow yield | 1.8% | Weak | 2.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 54.3% | Good | 58.6% |
| Operating margin | 19% | Good | 7.8% |
| Net margin | 11.6% | Good | 2.8% |
| Return on equity | 17.6% | Good | 5.7% |
| Return on assets | 9.6% | Good | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 45.5% | Good | 10.8% |
| EPS growth / year | -33.9% | Weak | 10.2% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.01× | Good | 0.48× |
| Net debt / EBITDA | -4.24× | Good | 1.58× |
| Current ratio | 3.91× | Good | 2.35× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow KNSA and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.